Potent induction of apoptosis by givinostat in BCR-ABL1-positive and BCR-ABL1-negative precursor B-cell acute lymphoblastic leukemia cell lines
- 1 September 2017
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 60, 129-134
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemiaGenes & Cancer, 2016
- Inhibitors of histone deacetylase as antitumor agents: A critical reviewBioorganic Chemistry, 2016
- Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphomaJournal of Oncology Pharmacy Practice, 2016
- An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenograftsCell Death & Disease, 2016
- Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALLClinical Cancer Research, 2015
- Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitorsCancer, 2008
- Histone-deacetylase inhibitors: novel drugs for the treatment of cancerNature Reviews Drug Discovery, 2002
- Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed CellsJNCI: Journal of the National Cancer Institute, 2000
- Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53Oncogene, 1999
- Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemiaBlood, 1991